
TRAX Stock Forecast & Price Target
TRAX Analyst Ratings
Bulls say
First Tracks is expected to have strong financials with a positive outlook as it anticipates its FDA Fast Track Designation for ANB033 to be a success. With the company's unique approach and strong pipeline, the positive results from its clinical trials and potential regulatory approvals, we expect strong financial growth and potential for significant future revenue. However, there are potential risks such as safety concerns or competition from other treatments, which could impact the company's success.
Bears say
First Tracks is an early-stage biotechnology company with a narrow focus on immunology therapeutics, limiting its potential market and revenue opportunities. The company also faces stiff competition from established pharmaceutical companies and regulatory hurdles in getting its drugs to market. Additionally, the company's financials show a negative trend, with increasing losses and decreasing cash reserves, indicating potential financial instability in the future.
This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares